SVAIX | VIVIX | SVAIX / VIVIX | |
Total Expense Ratio | 0.81 | 0.04 | 2,025% |
Annual Report Gross Expense Ratio | 0.93 | 0.04 | 2,325% |
Fund Existence | 21 years | 27 years | - |
Gain YTD | 12.062 | 9.748 | 124% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 5000000 | 20% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.67B | 208B | 4% |
Annual Yield % from dividends | 3.20 | 2.09 | 153% |
Returns for 1 year | 4.94 | 4.64 | 106% |
Returns for 3 years | 29.78 | 42.98 | 69% |
Returns for 5 years | 66.29 | 71.78 | 92% |
Returns for 10 years | 45.95 | 129.40 | 36% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JAGLX | 75.17 | 0.46 | +0.62% |
Janus Henderson Global Life Sciences T | |||
GSMVX | 16.78 | 0.04 | +0.24% |
Goldman Sachs Small/Mid Cap Equity Instl | |||
RAMHX | 38.79 | 0.04 | +0.10% |
American Funds American Balanced R2E | |||
SGQCX | 42.96 | -0.03 | -0.07% |
DWS International Growth C | |||
TIISX | 13.84 | -0.09 | -0.65% |
Nuveen Quant Intl Small Cap Eq R6 |